PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend
Phase 1
Terminated
- Conditions
- Kidney Failure
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2008-09-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT00150319
- Locations
- 🇺🇸
Pfizer Investigational Site, Austin, Texas, United States
12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.
Phase 2
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2007-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 625
- Registration Number
- NCT00150254
- Locations
- 🇺🇸
Pfizer Investigational Site, Houston, Texas, United States
Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)
Phase 3
Completed
- Conditions
- Macular Degeneration
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2007-05-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT00150202
- Locations
- 🇯🇵
Pfizer Investigational Site, Kyoto, Japan
To Evaluate the Safety and Efficacy of Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy.
Phase 3
Completed
- Conditions
- Diabetic Neuropathy, Painful
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2007-01-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 384
- Registration Number
- NCT00150423
Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
Phase 3
Completed
- Conditions
- Seizure Disorder, Partial
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 337
- Registration Number
- NCT00150293
- Locations
Pfizer Investigational Site
To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Postherpetic Neuralgia.
Phase 3
Completed
- Conditions
- Neuralgia
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2006-12-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 276
- Registration Number
- NCT00150436
A First In Human Study Of PF-00184562 In Healthy Volunteers
Phase 1
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2006-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT00150215
- Locations
- 🇺🇸
Pfizer Investigational Site, Austin, Texas, United States
Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.
Phase 3
Completed
- Conditions
- Anxiety Neuroses
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2006-07-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 511
- Registration Number
- NCT00150449
- Locations
Pfizer Investigational Site
Study To Examine Effect Of CP-866,087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects.
Phase 2
Completed
- Conditions
- Alcoholism
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2012-10-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 88
- Registration Number
- NCT00147576
- Locations
- 🇺🇸
Pfizer Investigational Site, San Antonio, Texas, United States
MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2013-09-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 79
- Registration Number
- NCT00147550
- Locations
- 🇺🇸
Pfizer Investigational Site, Cleveland, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath